所有图片(1)
About This Item
线性分子式:
(CH3)2SO
CAS号:
分子量:
78.13
Beilstein:
506008
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推荐产品
等級
pharmaceutical primary standard
蒸汽密度
2.7 (vs air)
蒸汽壓力
0.42 mmHg ( 20 °C)
自燃溫度
573 °F
expl. lim.
42 %, 63 °F
製造商／商標名
USP
存貨情形
not available in (Sales restrictions may apply)
折射率
n20/D 1.479 (lit.)
bp
189 °C (lit.)
mp
16-19 °C (lit.)
密度
1.10 g/mL (lit.)
應用
pharmaceutical (small molecule)
格式
neat
SMILES 字串
CS(C)=O
InChI
1S/C2H6OS/c1-4(2)3/h1-2H3
InChI 密鑰
IAZDPXIOMUYVGZ-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
相关类别
一般說明
本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持，请访问现行药典网站。
應用
Dimethyl sulfoxide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Dimethyl Sulfoxide Irrigation
- Dimethyl Sulfoxide Gel
- Dimethyl Sulfoxide Topical Solution
- Methylsulfonylmethane
注意
在室温下容易过冷并缓慢重融。 固化产品可以通过加热至室温来重新液化，而不会损害产品。
分析報告
这些产品仅供测试和分析使用。它们不适用于人类或动物的给药，不可用于诊断、治疗或治愈任何疾病。
其他說明
可能适用相应的销售限制。
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Dimethyl Sulfoxide Topical Solution
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 1414-1414 (2020)
Methylsulfonylmethane
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 32(3), 5097-5097 (2020)
Phillip McDonagh et al.
Veterinary microbiology, 174(3-4), 438-447 (2014-12-04)
Feline infectious peritonitis (FIP), a feline coronavirus (FCoV) induced disease, is almost invariably fatal with median life expectancy measured in days. Current treatment options are, at best, palliative. The objectives of this study were to evaluate a panel of nineteen
Claudia C Faria et al.
Cancer research, 75(1), 134-146 (2014-11-14)
Medulloblastoma is the most common malignant pediatric brain tumor, with metastases present at diagnosis conferring a poor prognosis. Mechanisms of dissemination are poorly understood and metastatic lesions are genetically divergent from the matched primary tumor. Effective and less toxic therapies
S L Khaw et al.
Leukemia, 28(6), 1207-1215 (2014-01-10)
Overexpression of the prosurvival protein Bcl-2 marks many B-lymphoid malignancies and contributes to resistance to many commonly used chemotherapeutic agents. The first effective BH3 mimetic inhibitors of Bcl-2, ABT-737 and navitoclax, also target Bcl-xL, causing dose-limiting thrombocytopenia. This prompted the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门